Cost-effectiveness analysis in pharmacogenomics

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 643-646

  Payne, Katherine ^a   Shabaruddin, Fatiha H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cost effectiveness analysis; Critical appraisal; Pharmacogenomics

Indexed keywords

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FUNDING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HIGH THROUGHPUT SCREENING; MATHEMATICAL ANALYSIS; NOTE; PHARMACOGENOMICS; REIMBURSEMENT; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; PHARMACOGENETICS;

EID: 77951547524     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.45     Document Type: Note

References (27)

1. Sculpher M, Drummond M, Buxton M: The iterative use of economic evaluation as part of the process of health technology assessment. J. Health Serv. Res. Policy 2(1), 26-30 (1997).
2. Drummond M, Sculpher M, Torrance GW et al.: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
3. Elliott RA, Payne K: Essentials of Economic Evaluation in Health Care. The Pharmaceutical Press, London, UK (2005).
4. Payne K: Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Pharmacogenomics 9, 1-4 (2008).
5. Flowers CR, Veenstra D: The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22(8), 481-493 (2004).
6. Dervieux T, Bala M: Overview of the pharmacoeconomics of pharmacogenomics. Pharmacogenomics 7(8), 1175-1184 (2006).
7. Giacomini M, Miller F, O'Brien BJ: Economic considerations for health insurance coverage of emerging genetic tests. Community Genet. 6(2), 61-73 (2003).
8. Carlson JJ, Henrikson NB, Veenstra D et al.: Economic analyses of human genetics services: a systematic review. Genet. Med. 7(8), 519-523 (2005).
9. Jarrett J, Mugford M: Genetic health technology and economic evaluation. Appl. Health Econ. Health Policy 5(1), 27-35 (2006).
10. Phillips KA, van Bebber SL: A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5(8), 1139-1149 (2004).
11. Vegter S, Boersma C, Rozenbaum M et al.: Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 26(7), 569-587 (2008).
12. Rogowski W: Genetic screening by DNA technology: a systematic review of health economic evidence. Int. J. Technol. Assess. Health Care 22(3), 327-337 (2006).
13. Payne K, Newman WG, Gurwitz D et al.: TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Per. Med. 6(1), 103-113 (2009).
14. Furuta T, Shirai N, Kodaira M et al.: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther. 81(4), 521-528 (2007).
15. Meckley LM, Gudgeon JM, Anderson JL et al.: A policy model to evaluate the benefts, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1), 61-74 (2010).
16. Carlson JJ, Garrison LP, Ramsey SD et al.: The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20-27 (2009).
17. Vegter S, Perna A, Hiddema W et al.: Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: infuence of the ACE insertion/deletion polymorphism. Pharmacogenet. Genomics 19(9), 695-703 (2009).
18. Cooper NJ, Sutton AJ, Ades AE et al.: Use of evidence in economic decision models: practical issues and methodological challenges. Health Econ. 16, 1277-1286 (2007).
19. Claxton K: Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 26(9), 781-798 (2008).
20. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. NICE, London, UK (2008).
21. Centre for Reviews and Dissemination. NHS Economic evaluation database handbook. University of York, York, UK (2007).
22. Philips Z, Bojke L, Sculpher M et al.: Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24(4), 355-371 (2006).
23. Garrison LP, Carlson RJ, Carlson JJ et al.: Review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab. Rev. 40(2), 377-401 (2008).
24. House of Lords Science and Technology Committee. Genomic medicine. The Stationery Offce Limited, London, UK (2009).
25. US Department of Health and Human Services. Federal coordinating council for comparative effectiveness research report to The President and The Congress. US Department of Health and Human Services, Washington DC, USA (2009).
26. Sculpher M, Claxton K: Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty-when is there suffcient evidence. Value Health 8, 433-446 (2005).
27. Sutton AJ, Cooper NJ, Goodacre S et al.: Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests. Med. Decis. Making 28, 650-667 (2008).